Session » SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Date: Sunday, November 13, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1454

A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study

1:00PM-3:00PM: Abstract Number: 1476

Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1468

Apathy Measurement in a Cohort of Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1479

Association of Neuromyelitis Optica and Systemic Lupus Erythematosus: Analysis of National Inpatient Sample

1:00PM-3:00PM: Abstract Number: 1472

Autoantibodies Against Tripartite-Motif 72 Protein (TRIM72) in Systemic Lupus Erythematosus Patients and in a Lupus Mouse Models with Myocarditis, Can Compromise Membrane Repair in Cardiomyocytes Potentially Contributing to Cardiovascular Disease Progression

1:00PM-3:00PM: Abstract Number: 1457

Baseline Characteristics of a Longitudinal, Multinational, Multiethnic Study of Lupus Patients, with or Without Lupus Nephritis

1:00PM-3:00PM: Abstract Number: 1466

Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores

1:00PM-3:00PM: Abstract Number: 1485

Characterization of Regulatory Receptors on Plasmacytoid Dendritic Cells in Lupus

1:00PM-3:00PM: Abstract Number: 1465

Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort

1:00PM-3:00PM: Abstract Number: 1446

Contrast Enhaced Articular Magnetic Resonance Imaging (MRI) and Health Related Quality of Life in SLE Patients

1:00PM-3:00PM: Abstract Number: 1451

Delayed Sleep Phase Syndrome Characterizes Circadian Disorder in Patients with Active SLE

1:00PM-3:00PM: Abstract Number: 1481

Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis

1:00PM-3:00PM: Abstract Number: 1467

Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience

1:00PM-3:00PM: Abstract Number: 1475

Epidemiology of Acute Ischemic Stroke in Patients with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1483

Etiology of Elevated Serum Creatinine in Patients with Systemic Lupus Erythematosus at Presentation and Association of Crescents in Renal Biopsy with Rapidly Progressive Renal Failure in a Lupus Cohort

1:00PM-3:00PM: Abstract Number: 1459

Evolution of Subjective Cognitive Impairment Overtime in SLE Patients: Bayesian Longitudinal Item Response Theory Modelling

1:00PM-3:00PM: Abstract Number: 1462

Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis

1:00PM-3:00PM: Abstract Number: 1445

Gastrointestinal Manifestations in Systemic Lupus Erythematosus Are Associated with High Disease Activity and Mortality: A Nationwide Cohort Study from India

1:00PM-3:00PM: Abstract Number: 1455

Immune Thrombocytopenic Purpura and Subsequent Development of Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1450

Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis

1:00PM-3:00PM: Abstract Number: 1449

Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study

1:00PM-3:00PM: Abstract Number: 1440

Interrelation of T-cell Cytokines and Autoantibodies in Lupus Nephritis: A Cross-sectional Study

1:00PM-3:00PM: Abstract Number: 1480

Is Lupus Podocytopathy a New Variant of Lupus Nephritis?

1:00PM-3:00PM: Abstract Number: 1482

Latent Tuberculosis Infection and Its Associations with Clinical and Serological Parameters in Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1456

Latin-American Systemic Lupus Erythematosus Clusters

1:00PM-3:00PM: Abstract Number: 1443

Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features

1:00PM-3:00PM: Abstract Number: 1484

Management of the Heightened Risk for Clinical Events from Atherosclerotic Cardiovascular Disease (ASCVD) in an Established Cohort of Lupus Erythematosus Patients

1:00PM-3:00PM: Abstract Number: 1460

Neuropsychiatric Lupus in Late and Early Onset Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-analysis

1:00PM-3:00PM: Abstract Number: 1464

Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations

1:00PM-3:00PM: Abstract Number: 1444

Patients with Lupus Pericarditis Have the Impact on the Poor Survival Outcome: A Retrospective Cohort Study

1:00PM-3:00PM: Abstract Number: 1452

Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis

1:00PM-3:00PM: Abstract Number: 1453

Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus

1:00PM-3:00PM: Abstract Number: 1477

Prevalence and Risk Factors of Fragility Fractures in Systemic Lupus Erythematosus: A Longitudinal Study over 12 Years

1:00PM-3:00PM: Abstract Number: 1441

Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program

1:00PM-3:00PM: Abstract Number: 1474

Quinolinic Acid, a Kynurenine/Tryptophan Pathway Metabolite, Correlates with Abnormalities in Brain Structure and Function in SLE

1:00PM-3:00PM: Abstract Number: 1469

Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1442

Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1447

Serum Cytokine Profiling Reveals Elevated Levels of S100A8/A9 and MMP-9 in Systemic Lupus Erythematosus Patients with Cognitive Impairment Independently of Disease Activity and Inflammatory Markers

1:00PM-3:00PM: Abstract Number: 1463

Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria

1:00PM-3:00PM: Abstract Number: 1458

Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment

1:00PM-3:00PM: Abstract Number: 1461

The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis

1:00PM-3:00PM: Abstract Number: 1471

Trends and Predictors of Hospitalizations Due to Acute Myocardial Infarction in Systemic Lupus Erythematosus Patients

1:00PM-3:00PM: Abstract Number: 1473

Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment

1:00PM-3:00PM: Abstract Number: 1478

Urine ALCAM Is a Strong Predictor of Lupus Nephritis

1:00PM-3:00PM: Abstract Number: 1448

Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares

1:00PM-3:00PM: Abstract Number: 1470

Work Disability and Function in Systematic Lupus Erythematosus (SLE): Results from a Mixed-Methods Exploratory Canadian Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].